Health Condition 1: I878- Other specified disorders of veins
Conditions
Interventions
Intervention1: Combination sclerosant agent: Combination of 2 ml of sodium tetradecyl sulfate + 2 ml lipiodol + 6 ml (12IU) bleomycin.
Intervention will be carried out every 4 weeks depending on the r
Sponsors
Datta Meghe Institue of Higher Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: Patients having slow flow vascular malformation who have not undergone any invasive intervention for venous malformation. Patients willing to participate in study and giving written informed consent.
Exclusion criteria
Exclusion criteria: Patients having high flow vascular malformation. Patients with slow flow vascular malformation who had underwent prior invasive intervention. Pregnant women with slow flow vascular malformation. Patients not willing to participate and not giving consent for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| post-intervention change in size of vascular malformationTimepoint: post-intervention change in size of vascular malformation at every sclerotherapy cycle and 3 months after last cycle of sclerotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome in form of any adverse effects of sclerotherapy in intervention & control group.Timepoint: Adverse events if present will be recorded during every sclerotherapy session & during follow up period at 3 months after last cycle of sclerotherapy. | — |
Countries
India
Contacts
Public ContactDr NAMRATA
Datta meghe Institue of Higher Education and Research, Sawangi meghe, Wardha, Maharashtra
Outcome results
None listed